Rhumbline Advisers Eq Rx, Inc. Transaction History

Rhumbline Advisers

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$1.66 - $2.31 $31,317 - $43,580	18,866 Added 4.16%	472,134 $1.05 Million
Q2 2023 Aug 08, 2023	BUY	$1.61 - $1.96 $252,489 - $307,378	156,826 Added 52.9%	453,268 $843,000
Q1 2023 May 11, 2023	BUY	$1.8 - $2.83 $13,690 - $21,524	7,606 Added 2.63%	296,442 $575,000
Q4 2022 Feb 14, 2023	BUY	$2.05 - $5.5 $10,153 - $27,241	4,953 Added 1.74%	288,836 $711,000
Q3 2022 Nov 10, 2022	BUY	$0.94 - $5.99 $77,678 - $494,995	82,637 Added 41.06%	283,883 $1.41 Million
Q2 2022 Aug 11, 2022	BUY	$3.2 - $5.69 $643,987 - $1.15 Million	201,246 New	201,246 $944,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.